Hims & Hers Is Pricing In a 13% Swing — Retail Is Already Picking Sides
With HIMS, AMAT, and CSCO all reporting, social sentiment is locked in on the GLP-1 pivot story — and the options market agrees
Ticker Ratings
If earnings season had a reality TV bracket, this week's $HIMS report would be the dramatic rose ceremony. Bloomberg's Week Ahead segment flagged that options markets are pricing in a ±13% move post-earnings — wild even by meme-stock standards — driven entirely by the company's whiplash pivot from Novo Nordisk competitor to Novo Nordisk retail partner on GLP-1 medications. The legal overhang that's been haunting HIMS like a bad ex? JP Morgan just slapped it with an Overweight rating, calling the partnership a genuine turning point.
Meanwhile, $AMAT reports Thursday with UBS turning bullish, riding the AI capex wave that YouTube channel The Traveling Trader estimates has hyperscalers doubling spend to over $700 billion — a cycle that Paul Tudor Jones believes still has 1-2 years of runway before the inevitable, quote, "breathtaking correction." For now, the semiconductor equipment names are still getting invited to the party.
Retail isn't being subtle: HIMS is the sentiment darling of the week, AMAT is the quiet overachiever, and anyone still sleeping on the GLP-1 partnership story is basically showing up to the finale having skipped all the episodes.